

# Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/L30FC27C0750EN.html>

Date: December 2019

Pages: 66

Price: US\$ 3,500.00 (Single User License)

ID: L30FC27C0750EN

## Abstracts

Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019

### SUMMARY

According to the recently published report 'Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.

The report 'Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with

respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 9 and 5 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Oncology and Ophthalmology which include indications Parkinson's Disease, Neurodegenerative Diseases, Alzheimer's Disease, Ocular Hypertension, Open-Angle Glaucoma, Pulmonary Hypertension and Solid Tumor.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)

The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted

therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Arrien Pharmaceuticals LLC

Cerevel Therapeutics LLC

D. Western Therapeutics Institute Inc

Denali Therapeutics Inc

E-scape Bio Inc

GlaxoSmithKline Plc

H. Lundbeck AS

Imago Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Lead Discovery Center GmbH

Merck & Co Inc

NeuBase Therapeutics Inc

Oncodesign SA

Origenis GmbH

Voronoi

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles

Antisense Oligonucleotides to Inhibit LRRK2 and SNCA for Parkinson's Disease - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
ARN-1104 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
DNL-151 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indication, H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Arrien Pharmaceuticals LLC, H2 2019  
Pipeline by Cerevel Therapeutics LLC, H2 2019  
Pipeline by D. Western Therapeutics Institute Inc, H2 2019  
Pipeline by Denali Therapeutics Inc, H2 2019  
Pipeline by E-scape Bio Inc, H2 2019  
Pipeline by GlaxoSmithKline Plc, H2 2019  
Pipeline by H. Lundbeck AS, H2 2019  
Pipeline by Imago Pharmaceuticals Inc, H2 2019  
Pipeline by Ionis Pharmaceuticals Inc, H2 2019  
Pipeline by Lead Discovery Center GmbH, H2 2019  
Pipeline by Merck & Co Inc, H2 2019  
Pipeline by NeuBase Therapeutics Inc, H2 2019  
Pipeline by Oncodesign SA, H2 2019  
Pipeline by Origenis GmbH, H2 2019  
Pipeline by Voronoi, H2 2019  
Dormant Projects, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Arrien Pharmaceuticals LLC

Cerevel Therapeutics LLC

D. Western Therapeutics Institute Inc

Denali Therapeutics Inc

E-scape Bio Inc

GlaxoSmithKline Plc

H. Lundbeck AS

Imago Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Lead Discovery Center GmbH

Merck & Co Inc

NeuBase Therapeutics Inc

Oncodesign SA

Origenis GmbH

Voronoi

## I would like to order

Product name: Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/L30FC27C0750EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L30FC27C0750EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970